Figure 1.

Mutational profile of stage III non-small cell lung cancer. Oncoprint of clinical outcomes (survival status and local-regional failure) and 20 most frequently mutated genes identified by Memorial Sloan Kettering-Integrated Mutational Profiling of Actionable Cancer Targets clinical tumor mutational profiling in 110 patients with stage III non-small cell lung cancer. Genes are ordered based on mutational frequency. Mutational types are color-coded (black, deleterious mutations defined as either frameshift or nonsense mutation; green, missense mutation; gray, no alterations).